CAR T-Cell trial for rare lymphoma halted after just one patient
NCT ID NCT06912529
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tested a CAR T-cell treatment called axicabtagene ciloleucel in people with a rare type of lymphoma (PMBCL) that came back or didn't respond to initial therapy. The goal was to see if the treatment could make the cancer disappear. Only one person enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster
Münster, 48149, Germany
Conditions
Explore the condition pages connected to this study.